77PPreliminary results from a phase 1 study of AB122, a programmed cell death-1 (PD-1) inhibitor, in patients with advanced solid malignancies. (17th December 2018) - Seitz, L C; Rieger, A; Berry, W; Ashok, D; Direnzo, D; Jin, L; Lee, S J; Park, A; Piovesan, D; Tan, J B L; Walters, M J; Karakunnel, J